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ABSTRACT
Tissue hypoxia plays a key role in the development and progres-
sion of many kidney diseases. Blood oxygenation level-
dependent magnetic resonance imaging (BOLD-MRI) is the
most promising imaging technique to monitor renal tissue oxy-
genation in humans. BOLD-MRI measures renal tissue deoxy-
haemoglobin levels voxel by voxel. Increases in its outcome
measure R2* (transverse relaxation rate expressed as per sec-
ond) correspond to higher deoxyhaemoglobin concentrations
and suggest lower oxygenation, whereas decreases in R2* indi-
cate higher oxygenation. BOLD-MRI has been validated against
micropuncture techniques in animals. Its reproducibility has
been demonstrated in humans, provided that physiological and
technical conditions are standardized. BOLD-MRI has shown
that patients suffering from chronic kidney disease (CKD) or
kidneys with severe renal artery stenosis have lower tissue oxy-
genation than controls. Additionally, CKD patients with the
lowest cortical oxygenation have the worst renal outcome.
Finally, BOLD-MRI has been used to assess the inﬂuence of
drugs on renal tissue oxygenation, and may offer the possibility
to identify drugs with nephroprotective or nephrotoxic effects
at an early stage. Unfortunately, different methods are used to
prepare patients, acquire MRI data and analyse the BOLD
images. International efforts such as the European Cooperation
in Science and Technology (COST) action ‘Magnetic Resonance
Imaging Biomarkers for Chronic Kidney Disease’
(PARENCHIMA) are aiming to harmonize this process, to
facilitate the introduction of this technique in clinical practice in
the near future. This article represents an extensive overview of
the studies performed in this ﬁeld, summarizes the strengths
and weaknesses of the technique, provides recommendations
about patient preparation, image acquisition and analysis, and
suggests clinical applications and future developments.
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INTRODUCTION
Renal tissue ischaemia is one of the main mechanisms leading to
acute kidney injury and mounting evidence suggests that renal tis-
sue hypoxia is a unifying factor in the development and progres-
sion of chronic kidney disease (CKD), irrespective of its cause [1].
Assessing renal tissue oxygenation in humans is therefore highly
relevant to clinical practice. Blood oxygenation level-dependent
magnetic resonance imaging (BOLD-MRI) has become a widely
used method to estimate renal tissue oxygenation, although its use
is thus far largely restricted to the research setting.
This review paper, written by the European Cooperation in
Science and Technology (COST) action ‘Magnetic Resonance
Imaging Biomarkers for Chronic Kidney Disease’
(PARENCHIMA) group, provides an overview of the technique
and pitfalls of BOLD-MRI, as well as a summary of all renal
BOLD-MRI studies performed in humans so far. These studies
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are summarized in tables under ‘Supplementary data’. This re-
view paper also identifies gaps in knowledge and provides rec-
ommendations about patient preparation, image acquisition
and analysis, and possible clinical applications.
METHODOLOGY
A comprehensive search of PubMed and Ovid MEDLINE was
performed using the following pre-defined MeSH terms: blood,
oxygenation, MRI and kidney (renal). Review articles or studies
performed in animals were not included, except those that vali-
dated BOLD-MRI against directly measured renal tissue oxygena-
tion (micropuncture). Renal cancer studies were excluded.
Only original articles written in English and published in
peer-reviewed journals before the 31 December 2017 were se-
lected and divided into five categories: validation of the tech-
nique, CKD, renal artery stenosis, transplantation and
dietary/drug intervention. Each study is summarized in Excel
tables (Supplementary data).
PHYSIOLOGY OF RENAL TISSUE
OXYGENATION AND PRINCIPLES OF
BOLD-MRI
Renal tissue oxygenation is the net balance between oxygen de-
livery and demand. Delivery depends on renal blood flow
(RBF), haemoglobin levels, blood pH and oxygen saturation,
whereas oxygen demand depends on tissue metabolic require-
ments and the oxygen-consuming active tubular transport of
electrolytes [2]. Decreases in global RBF do not necessarily lead
to a reduction in oxygen delivery due to the presence of sub-
stantial arterio-venous shunting of oxygen that can vary accord-
ing to metabolic needs. Inversely, an increase in RBF does not
necessarily increase tissue oxygenation since it also leads, at
constant filtration fraction (FF), to a higher glomerular filtra-
tion rate (GFR), higher amounts of filtered sodium and thus in-
creased metabolic demands [3]. Together, these mechanisms
tightly control renal tissue oxygenation. Despite the fact that
each kidney receives10% of the cardiac output, local pO2 lev-
els are low. Micropuncture studies in animals have measured
tissue pO2 of around 40–50mmHg in the cortex and as low as
10–20mmHg in the inner medulla [4]. These pO2 levels are at
the steep part of the oxygen dissociation curve for haemoglobin,
meaning that small changes in local pO2 lead to relatively large
changes in the percentage of saturated haemoglobin.
BOLD-MRI uses the specific paramagnetic properties of
deoxyhaemoglobin to assess renal tissue oxygenation. Its out-
come measure is the so-called R2* value, which varies inversely
with local oxygenation. This apparent relaxation rate R2* (or
decay rate, defined as 1/T2* and expressed as per second) is
measured voxel by voxel in each kidney by BOLD-MRI. The
R2* value of each voxel is influenced by microscopic inhomoge-
neities in the static magnetic field, largely due to the effect of
deoxyhaemoglobin. As such, the decay rate R2* in a voxel will
be enhanced when the local deoxyhaemoglobin concentration
is increased. Hence, assuming that blood pO2 is in equilibrium
with tissue pO2, low R2* values indicate high tissue oxygena-
tion, while high R2* values indicate low tissue oxygenation [5].
BOLD-MRI is performed without the administration of con-
trast agents, which makes it attractive for patients with de-
creased renal function.
VALIDATION OF KIDNEY BOLD-MRI
The aim of BOLD-MRI is to measure renal tissue oxygenation.
The actual ‘gold standard’ for tissue oxygenation is direct mea-
surement with micro-electrodes placed in the renal cortex and
medulla. For obvious reasons, this is not possible in humans,
and comparison with the gold standard has only been per-
formed in animals.
In 1996, Prasad et al. published their landmark paper on
the feasibility of the evaluation of intrarenal oxygenation by
BOLD-MRI [6]. They studied seven healthy young subjects
and found, as expected, a decreased R2* (indicating increased
pO2) during administration of furosemide; this observation
was in line with prior research using microelectrodes that
had shown an increase in medullary pO2 due to the
furosemide-induced reduction in oxygen-consuming active
electrolyte transport. In the subsequent years numerous
authors confirmed the effects of furosemide in pigs [7],
healthy humans [8] and patients [9].
Only a decade later (in 2005) Pedersen et al. took up the
challenge to quantitatively validate the technique [7]. They
compared BOLD-MRI measurements in renal cortex and me-
dulla to those of pO2 electrodes inserted in the contralateral
kidney of eight anaesthetized pigs. They were able to establish
a linear relationship between measured pO2 and R2* over the
pO2 range of 0.2–10 kPa in both the cortex and the medulla.
For the cortex this resulted in a pO2 [kPa] ¼ R2* [1/s]21/1.2
and for the medulla pO2 ¼ R2*25/1.7. A study performed by
Warner et al. (2011) tested the acute effects of furosemide and
acetazolamide in four series of pigs (total n¼ 21) with consecu-
tive measurements of cortical and medullary oxygenation by
BOLD-MRI and Clark electrodes 5–7 days apart [10]. They
also found a linear relationship, namely pO2 [kPa] ¼R2* [1/
s]20/1.3 for the cortex and for the medulla pO2 ¼ R2*20/
1.5. The reported pO2 range was narrower than that of
Pedersen et al., i.e. 3.1–7.6 kPa, which may explain some of the
differences in calculated coefficients and Y-intercepts. Up to
now, the two independent studies by Pedersen et al. and
Warner et al. serve as the most cited calibration data on renal
BOLD-MRI [7, 10]. Recently, Zhang et al. provided a method
to relate R2* measurements to blood and tissue pO2 [11].
So far, three studies have specifically assessed the repro-
ducibility of BOLD-MRI in humans. All used the classical re-
gion-of-interest (ROI) technique for image analysis (see
below). Li et al. showed a 12% coefficient of variation (CV)
for day-to-day measurements in eight healthy subjects at
1.5 T [8]. Simon-Zoula et al. evaluated the reproducibility in
18 healthy volunteers during three subsequent MRI
acquisition on a single day, with short interruptions between
sessions [12]. They reported CVs of R2* values of 3% and 4%
in the medulla and cortex, respectively. Khatir et al. reported
CVs of 8% for cortex and medulla in 11 CKD patients exam-
ined at 1–2 week intervals, as compared with 5.6% and 3.6%
in controls [13].
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PATIENT PREPARATION
Many factors may alter cortical and medullary R2* values and
should be taken into account. Prasad et al. were the first to
show that hydration status influences the BOLD signal. They
reported decreases up to 30% in medullary R2* values after an
acute oral water load of 20mL/kg in young healthy volunteers
[14]. Most BOLD-MRI studies therefore standardize water in-
take, although approaches differ: some perform BOLD-MRI af-
ter an overnight or 4-h fast [15] whereas others prescribe a
constant hourly water intake, in general of 1.5mL/kg/h [16].
A theoretical disadvantage of hydration is that differences in
R2* may be ‘washed out’ by hydration, but this only occurs at
extreme water intake (1 L intake in 15min) [16]. The clear ad-
vantage of hydration is its feasibility in patients; the authors
therefore prefer standardized hydration protocols.
Dietary salt intake also influences R2* values. This has been
demonstrated in a cross-over study that included young nor-
motensive and untreated hypertensive male volunteers [17].
After 5 days of a low-salt diet, medullary R2* values were signif-
icantly lower than after a 5 day high-salt diet. Despite the avail-
ability of these data in the literature, less than half of the
published studies have controlled salt intake.
Furthermore, as expected, renal tissue oxygenation is influ-
enced by carbogen and oxygen breathing [18].
Some questions concerning patient preparation remain unan-
swered. For example, no study has investigated whether there is a
circadian rhythm in the BOLD signal. Besides, plasma osmolal-
ity, pH and temperature (affecting O2 dissociation), iron status
(affecting tissue para-magnetic properties) and carbon monoxide
levels (tobacco use) could all potentially affect the BOLD-MRI
signal. None of the latter factors has been studied for this purpose
yet. However, subjects are advised to avoid smoking prior to the
MRI examination and a delay of 1–2weeks is usually maintained
in case of fever or intravenous (IV) iron perfusion.
MRI ACQUISITION
The most common techniques used for human renal BOLD-MRI
experiments are single shot echo planar imaging (EPI) [6] andmul-
tiple gradient echo (GRE) imaging [19]. Almost all measurements
are expiratory breath-hold acquisitions because T2*-weighted renal
MRI is prone to motion artefacts. To date, all published studies of
the human kidney have been performed at either 1.5 or 3T field
strengths. The most recent publications show preference for 3T
due to improved signal-to-noise ratio (SNR) and better T2* weight-
ing secondary to T2* shortening. R2* increases with increasing field
strength. For example, the R2* value of the healthy medulla at 3T
is almost twice the one acquired at 1.5T. However, artefacts caused
by bulk magnetic susceptibility (BMS) effects and water-fat chemi-
cal shift are also magnified at 3T field strengths, but remain at an
acceptable level when compared with 1.5T.
Single shot EPI is a robust approach to reduce motion artefacts
and it offers the highest temporal resolution (<100ms).
Unfortunately, EPI is sensitive to BMS artefacts caused by the shape
of the human body (organs) and by magnetic susceptibility varia-
tions within the body, sometimes leading to image blurring and
geometrical distortions. Image distortions are amplified at higher
magnetic field strengths, particularly in regions with poormagnetic
field homogeneity. To address these challenges, two-dimensional
multiple gradient recalled echo (2D mGRE) sequences with signal
collection at multiple echoes after each excitation pulse have been
introduced and are the most frequently used for renal R2* map-
ping. Typically 8, 12 or 16 individual T2*-weighted images of a sin-
gle slice, corresponding to different echoes, are measured within a
single breath-hold of 17–20 s. However, multislice 2D mGRE as
well as 3D mGRE were also successfully implemented during a
breath-hold of <23 s [20]. A detailed discussion of the acquisition
parameters is beyond the scope of this article, and partly based on
expert opinion. The acquisition parameters [repetition time (TR),
echo time (TE) interval, acquisition voxel size, flip angle and re-
ceiver bandwidth] have to be carefully chosen to maintain the
minimum SNR>2 necessary to avoid errors in T2* fitting as the
result of noise at higher TE. For more details, see Supplementary
data, Table S1. It should be emphasized that the SNR>2 is critical
for the robust assessment of the medulla. Both 2D mGRE as well
as EPI sequences suffer from magnitude and phase variations be-
tween odd and even echoes due to different phases of water and
fat signal components in renal tissue (in- and out-phase effects).
However, these artefacts are usually satisfactorily suppressed dur-
ing mono-exponential least square fitting of T2*.
Despite these improvements, it remains difficult to overcome
all scanner-related and other non-renal factors that influence the
BOLD signal. This hampers the comparison of absolute R2* val-
ues across sites. One way to partly overcome this limitation is to
perform a dynamic test (IV furosemide for example) and assess
the change in R2* signal. Another way is the use of analysis tech-
niques that are less dependent of the absolute R2* values and fo-
cus more on relative changes in R2* (12-layer concentric
objects—TLCO and fractional tissue hypoxia technique).
IMAGE ANALYSIS
Four major methods have been used thus far to analyse the
BOLD images and report the R2* values: ROI technique, TLCO
or ‘onion peel’ technique, the fractional tissue hypoxia and the
compartmental method. The basic principles, strengths and
weaknesses of each technique are summarized in Table 1, and
graphical examples are shown in Figure 1.
Several studies [9, 19, 21–22] have specifically assessed the
inter-observer variability (image analysis of the same subject by
two or more different observers) of these techniques. Piskunowicz
et al. reported inter-observer CVs with the ROI technique of 3.6%
and 6.8% of cortical and medullary R2* values in healthy volun-
teers, versus 5.7% and 12.5% in CKD. With the semi-automatic
TLCO technique, the same research group reported much lower
CVs of 2.2%, 2.0% and 3.1% in healthy, mild CKD and severe
CKD groups [21]. Cox et al. reported CVs of 4.1% in healthy vol-
unteers with the compartmental method [23].
Most authors agree that the ROI technique is reproducible
and easy to use in subjects with (near) normal renal function
(GFR), but unreliable in advanced CKD, due to its dependence
of the human eye to distinguish cortex from medulla. In CKD,
the TLCO technique has the lowest inter-observer variability,
whereas the fractional hypoxia technique is mostly used in
patients suffering from renal artery stenosis. The compartmen-
tal method needs confirmation in CKD patients.
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MAIN RESULTS OF CLINICAL STUDIES
Chronic kidney disease
According to the chronic hypoxia hypothesis, renal tissue
hypoxia is a unifying pathway in the development and progres-
sion of CKD, irrespective of its cause [1]. Many animal studies
support this hypothesis and intra-renal microelectrodes have
indeed measured decreased local tissue pO2 in several experi-
mental models of CKD [24, 25].
Initially, numerous BOLD-MRI studies in humans failed to
confirm the hypoxia hypothesis [16, 26]. This was probably due
to the lack of standardized patient preparation, suboptimal
FIGURE 1: Examples of different ways to analyse the images obtained with BOLD-MRI. (A) Small ROI technique. (B) TLCO technique. (C)
R2* proﬁle: the curve links the mean R2* value of each of 12 layers shown under B, and the red line depicts its steepness. (D) Fractional tissue
hypoxia. (E) Compartmental method.
Table 1. Overview of the actually used techniques to analyse BOLD images
Technique Principle Strengths Weaknesses
ROI Manual placement of circles (called
ROIs, 20–40 voxels each) in cortex
and medulla
 Provides separate information on cortical and medul-
lary R2*
 Difﬁcult to differentiate cortex
from medulla in advanced CKD
Most frequently used method, easy to perform  Low reproducibility in CKD
Medullary ROI selection may
be skewed by hypoxic regions in
the cortex
Fractional
hypoxia
Reports the percentage of R2* values
of manually selected renal paren-
chyma above a certain threshold
(usually 30 per second or >2.5 SDs
above the average R2*)
 This parameter is easily understood by clinicians  The threshold for hypoxia is
artiﬁcial
 No formal assessment of med-
ullary hypoxia
Compartment-
al method
The heterogeneity of renal oxygena-
tion and its gamma distribution of
R2* values is used to differentiate me-
dulla from the cortex
 Smaller inter-observer variability than classical ROI
technique
 Vulnerable to abdominal sus-
ceptibility artefact
 Allows analysis of separate cortical and medullary re-
sponse to drug challenge
 Inaccurate estimation in ad-
vanced CKD
TLCO or onion
peel
Division of renal parenchyma from
each slice in 12 layers of equal thick-
ness, reporting mean R2* of each
layer
 Semi-automatic procedure with lowest inter-observer
variability
 No formal anatomic distinction
between cortex and medulla
 Large surface of renal parenchyma analysed
 The steepness of the slope of the R2* curve con-
necting mean values of each layer depends less of ab-
solute R2* values
Renal BOLD-MRI: a statement paper ii25
study designs, low field strength (1.5 T) and the use of the small
ROI technique that is characterized by high inter-observer vari-
ability in CKD. Recent studies performed under standardized
conditions and high field strength (3.0 T) have reported higher
cortical R2* values in CKD compared with controls [9, 27]. Of
note, most studies have not measured RBF, which complicates
the interpretation of the results. In this respect, van der Bel et al.
have shown that R2* values correlate strongly with the FF
(GFR/effective renal plasma flow) in healthy volunteers, and
they recommend performing simultaneous BOLD-MRI and
phase contrast MRI to measure RBF in the renal artery [28].
This field was also hampered by the lack of prospective stud-
ies, but this has recently changed with the publication of Pruijm
et al. In their cohort of 112 CKD patients, 47 hypertensives and
24 healthy controls, CKD patients with high R2* values (>90th
percentile) had a faster yearly estimated GFR decline and more
often needed renal replacement therapy than those with lower
R2* values [29]. This study strongly supports the hypoxia hy-
pothesis and opens the door to more widespread implementa-
tion of renal BOLD-MRI in the clinical care for CKD patients.
Renal artery stenosis and arterial hypertension
The decrease in RBF that characterizes renal artery stenosis
(RAS) makes BOLD-MRI particularly suitable to probe tissue
oxygenation in the post-stenotic kidney. Studies in swine mod-
els of acute [30] and chronic [10] reductions in RBF have con-
firmed that BOLD-MRI is capable of detecting changes in renal
oxygenation that were independently confirmed using
implanted oxygen electrodes. Studies in human subjects with
>60% obstruction of the renal artery have enabled the determi-
nation of the haemodynamic significance of the stenosis.
Interestingly, cortical and medullary R2* values were preserved
in many patients with moderate obstructions of the renal artery,
despite a fall in stenotic kidney RBF and GFR by 30–35% [31].
This finding is consistent with observed adaptability of human
kidneys to moderate reductions of RBF. Repeat measurements
3 months later showed that their R2* values remained highly
stable [32]. Blunted responses to the loop diuretic furosemide
in these kidneys suggested that preservation of tissue oxygena-
tion was associated with attenuated active solute transport ac-
tivity and thereby oxygen consumption.
However, kidneys distal to severe luminal obstructions
showed more pronounced hypoxia [33] with increased tissue
injury, interstitial fibrosis and inflammation [34]. The degree of
renal hypoxia by BOLD-MRI in those stenotic kidneys corre-
lated directly with the severity of fall in single-kidney RBF and
serum injury biomarkers in the draining renal vein [32, 35].
The ability of BOLD-MRI to monitor therapeutic interven-
tions has been shown in groups of patients with RAS receiving
autologous mesenchymal stem cells into stenotic kidneys [36]
or pretreated with a mitochondrial targeted peptide before un-
dergoing renal revascularization [37]. In both studies, a fall in
R2* 3months after treatment was associated with a modest in-
crease in cortical perfusion. It should be emphasized that physi-
ological changes in renal work may limit the ability to detect
changes in R2*. For example, in subjects with high-grade renal
artery occlusion cortical and medullary R2* levels may appear
normal due to complete lack of glomerular filtration and solute
transport [38]. Some authors therefore propose interpretation
of BOLD measurements in correlation with parenchymal renal
volume and stenotic kidney GFR (measured by isotope renog-
raphy) to derive a biomarker that may predict a positive renal
functional response to revascularization [39].
Taken together, severe RAS may be characterized by either
marked renal hypoxia consistent with tissue injury, and/or
abolished response to furosemide, suggesting minimal residual
blood flow to the kidney. BOLD-MRImay be able to assist clini-
cal evaluation of RAS, but more data are needed to achieve clin-
ically relevant advances.
Transplantation
In 2005, Sadowski et al. showed the feasibility of using
BOLD-MRI in acute renal transplant rejection [40]. These
authors found lower medullary R2* values in the acute rejection
group compared with normally functioning transplants and
transplants with acute tubular necrosis (ATN), while cortical
R2* values were higher in ATN compared with the other
groups. These observations were confirmed by several subse-
quent studies and the medullary-to-cortical R2* ratio has since
been proposed as a marker to distinguish between these entities
[41, 42]. The technique has been proven to be reproducible in
subjects with good allograft function and its highest value
appears to lie in differentiating stable well-functioning allografts
from acute rejection, especially when decreased T2* values are
measured in both the medulla and cortex [43]. BOLD-MRI has
also been combined with perfusion and diffusion-weighted
MRI to better understand the natural evolution of transplanted
kidneys, their degree of fibrosis as well as the episodes of rejec-
tion/ATN that may occur when patients are followed over
time [44].
Drugs and diet
BOLD-MRI is well suited for monitoring changes following
acute dietary and/or pharmacologic manipulation. There are
numerous reports evaluating different drugs or diets and the
supplementary tables provide representative examples. Below is
a brief discussion summarizing drug studies to date.
As mentioned, intravenous furosemide leads to an acute de-
crease in medullary R2* values and the response to furosemide
is currently used as a functional parameter in studies with CKD
[16] and RAS [38].
Drugs that modulate the renin-angiotensin system are com-
monly used by renal patients and have been shown to decrease
R2* values in most but not all studies. Patients taking beta
blockers showed lower R2* values compared with those that do
not [45]. Inversely, increases in R2* have been observed after
the infusion of angiotensin II [46]. In addition, one could ob-
serve indirect effects of cyclooxygenase inhibitors resulting
in blunted response to water-loading in healthy young individ-
uals [14].
Overall, there is good experience to date in evaluating effects
of several drugs and diets with renal BOLD-MRI. Acute drug
effects on renal oxygenation may provide early insights in the
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mode of action of these drugs and their potential nephrotoxic/
protective effects.
DISCUSSION AND CONCLUSION
Overall, BOLD-MRI is a powerful tool to evaluate tissue oxy-
genation within the kidneys in humans. The method has been
validated against the gold standard (direct measurement of tis-
sue pO2) in animal studies, although more studies would be
welcome. The possibility to report per-kidney values is of par-
ticular interest for patients with RAS. Huge technical progress
has been achieved that has resulted in reduced acquisition times
(5–15min) and semi-automatic analysis protocols. However,
the current lack of head-to-head comparison with the gold stan-
dard in humans remains the main limitation of the technique.
Recent proof-of-concept BOLD-MRI studies in CKD
patients have provided strong arguments in favour of the
chronic hypoxia hypothesis [9, 27], and one study has illus-
trated its potential to predict renal function decline [29].
BOLD-MRI provides a wealth of information in patients with
severe vascular disease, although interpretation of the results is
difficult, and combination with measures of RBF, GFR or tissue
injury will clearly increase its usefulness.
BOLD-MRI is also a powerful tool to gain insight into the re-
nal effects of drugs, thanks to the ability to repeat the exam as of-
ten as needed without side effects or ionizing radiation burden. In
this regard, BOLD-MRI is of interest to pharmaceutical compa-
nies, since it has the potential to identify possible nephrotoxic or
nephroprotective properties of drugs at an early stage. The infor-
mation obtained with BOLD-MRI is increased when used in
combination with other MRI modalities that are able to assess
RBF (phase contrast, arterial spin labelling), oedema or tissue fi-
brosis (diffusion-weighted imaging, T1 mapping), as discussed
elsewhere in this NDT Supplement [47]. However, further stan-
dardization is needed, especially when it comes to patient prepa-
ration and image analysis. The recommended way to perform
BOLD-MRI, depending on the research question and the exam-
ined patient group, is summarized in Table 2. This statement is
based on the available literature and expert opinion, and may
therefore be subject to change in the future.
In conclusion, BOLD-MRI has come a long way and is al-
most ready for prime time; international collaborations such as
the ongoing COST action PARECHIMA offer unique opportu-
nities to accelerate its entrance in to clinical practice, most likely
in combination with other functional MRI modalities within a
single MRI session.
SUPPLEMENTARY DATA
Supplementary data are available at ndt online.
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